Skip to main content
Top
Published in: Drug Safety 11/2010

01-11-2010 | Systematic Review

Preventability of Drug-Related Harms — Part I

A Systematic Review

Authors: Professor Robin E. Ferner, Jeffrey K. Aronson

Published in: Drug Safety | Issue 11/2010

Login to get access

Abstract

‘Preventability’ is a crucial concept in the literature on adverse drug reactions (ADRs). We have carried out a systematic review in order to identify and analyse the approaches used to define ‘preventability’ in relation to ADRs. We have restricted this investigation to definitions of preventability and have not dealt with other aspects. We searched MEDLINE (1963–April 2009) and EMBASE (1980–April 2009), without language restriction, for papers in which preventability of ADRs was likely to be defined.
We found 234 papers, of which we retrieved 231. Of these, 172 either contained original definitions of preventability or referred to other papers in which preventability was defined. Forty contained no definition, and 19 were not relevant. In the 172 papers selected, we identified eight different general approaches to defining the preventability of ADRs: (1) analysis without explicit criteria; (2) assessment by consensus; (3) preventability linked to error; (4) preventability linked to standards of care; (5) preventability linked to medication-related factors; (6) preventability linked to information technology; (7) categorization of harmful treatments in explicit lists; and (8) a combination of more than one approach.
These approaches rely on two general methods: the judgement of one or more investigators or the use of pre-defined explicit criteria; neither is satisfactory. Specific problems include the weakness of consensus as a method (since experts can agree and yet be wrong), inadequacy of definition of standards of care, and circularity in several definitions of preventability. Furthermore, attempts to list all preventable effects are bound to be incomplete and will not always apply to an individual case.
We conclude that an approach based on analysis of the mechanisms of adverse reactions and their clinical features could be preferable; such an approach is described in a companion paper (Part II) in this issue of Drug Safety.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aronson JK, Ferner RE. Preventability of drug-related harms — part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010; 33(11): 995–1002PubMedCrossRef Aronson JK, Ferner RE. Preventability of drug-related harms — part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010; 33(11): 995–1002PubMedCrossRef
2.
go back to reference Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S79–90PubMedCrossRef Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S79–90PubMedCrossRef
3.
5.
go back to reference Takata GS, Mason W, Taketomo C, et al. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children’s hospitals. Pediatrics 2008; 121: e927–35PubMedCrossRef Takata GS, Mason W, Taketomo C, et al. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children’s hospitals. Pediatrics 2008; 121: e927–35PubMedCrossRef
6.
go back to reference Bigby J, Dunn J, Goldman L, et al. Assessing the preventability of emergency hospital admissions. Am J Med 1987; 3: 1031–6CrossRef Bigby J, Dunn J, Goldman L, et al. Assessing the preventability of emergency hospital admissions. Am J Med 1987; 3: 1031–6CrossRef
7.
go back to reference Dubois RW, Brook RH. Preventable deaths: who, how often, and why? Ann Intern Med 1988; 109(7): 582–9PubMedCrossRef Dubois RW, Brook RH. Preventable deaths: who, how often, and why? Ann Intern Med 1988; 109(7): 582–9PubMedCrossRef
8.
go back to reference Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 2004; 170(11): 1678–86PubMedCrossRef Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 2004; 170(11): 1678–86PubMedCrossRef
10.
go back to reference Morris CJ, Cantrill JA. Preventing drug-related morbidity: the development of quality indicators. J Clin Pharm Ther 2003; 28(4): 295–305PubMedCrossRef Morris CJ, Cantrill JA. Preventing drug-related morbidity: the development of quality indicators. J Clin Pharm Ther 2003; 28(4): 295–305PubMedCrossRef
11.
go back to reference Buetow SA, Sibbald B, Cantrill JA, et al. Appropriateness in health care: application to prescribing. Soc Sci Med 1997; 45(2): 261–71PubMedCrossRef Buetow SA, Sibbald B, Cantrill JA, et al. Appropriateness in health care: application to prescribing. Soc Sci Med 1997; 45(2): 261–71PubMedCrossRef
12.
go back to reference McDowell SE, Ferner HS, Ferner RE. The pathophysiology of medication errors: how and where they arise. Br J Clin Pharmacol 2009; 67(6): 605–13PubMedCrossRef McDowell SE, Ferner HS, Ferner RE. The pathophysiology of medication errors: how and where they arise. Br J Clin Pharmacol 2009; 67(6): 605–13PubMedCrossRef
13.
go back to reference Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140(10): 795–801PubMedCrossRef Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med 2004; 140(10): 795–801PubMedCrossRef
14.
go back to reference Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm 2003; 60(17): 1750–9PubMed Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm 2003; 60(17): 1750–9PubMed
15.
go back to reference Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228(2): 83–90PubMedCrossRef Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228(2): 83–90PubMedCrossRef
16.
go back to reference Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937–44PubMedCrossRef Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937–44PubMedCrossRef
17.
go back to reference Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995; 274(1): 29–34PubMedCrossRef Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995; 274(1): 29–34PubMedCrossRef
18.
go back to reference Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109(2): 87–94PubMedCrossRef Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109(2): 87–94PubMedCrossRef
19.
go back to reference Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289(9): 1107–16PubMedCrossRef Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289(9): 1107–16PubMedCrossRef
20.
go back to reference Ferner RE. The epidemiology of medication errors: the methodological difficulties. Br J Clin Pharmacol 2009; 67(6): 614–20PubMedCrossRef Ferner RE. The epidemiology of medication errors: the methodological difficulties. Br J Clin Pharmacol 2009; 67(6): 614–20PubMedCrossRef
21.
22.
go back to reference Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15–9PubMedCrossRef Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15–9PubMedCrossRef
23.
go back to reference van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf 2008; 17: 365–71PubMedCrossRef van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf 2008; 17: 365–71PubMedCrossRef
24.
go back to reference Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 2008; 31(6): 545–56PubMedCrossRef Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 2008; 31(6): 545–56PubMedCrossRef
25.
go back to reference Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54(12): 959–63PubMedCrossRef Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54(12): 959–63PubMedCrossRef
26.
go back to reference Darchy B, Le Mière E, Figuérédo B, et al. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med 1999; 159(1): 71–8PubMedCrossRef Darchy B, Le Mière E, Figuérédo B, et al. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med 1999; 159(1): 71–8PubMedCrossRef
27.
go back to reference Thomas EJ, Brennan TA. Incidence and types of preventable adverse events in elderly patients: population based review of medical records. BMJ 2000; 320: 741–4PubMedCrossRef Thomas EJ, Brennan TA. Incidence and types of preventable adverse events in elderly patients: population based review of medical records. BMJ 2000; 320: 741–4PubMedCrossRef
28.
go back to reference Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008; 178(12): 1563–9PubMedCrossRef Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008; 178(12): 1563–9PubMedCrossRef
29.
go back to reference Sari AB, Cracknell A, Sheldon TA. Incidence, preventability and consequences of adverse events in older people: results of a retrospective case-note review. Age Ageing 2008; 37(3): 265–9PubMedCrossRef Sari AB, Cracknell A, Sheldon TA. Incidence, preventability and consequences of adverse events in older people: results of a retrospective case-note review. Age Ageing 2008; 37(3): 265–9PubMedCrossRef
30.
go back to reference Hayward RA, Hofer TP. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer. JAMA 2001; 286(4): 415–20PubMedCrossRef Hayward RA, Hofer TP. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer. JAMA 2001; 286(4): 415–20PubMedCrossRef
31.
go back to reference Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324(6): 370–6PubMedCrossRef Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N Engl J Med 1991; 324(6): 370–6PubMedCrossRef
32.
go back to reference Brennan TA, Hebert LE, Laird NM, et al. Hospital characteristics associated with adverse events and substandard care. JAMA 1991; 265(24): 3265–9PubMedCrossRef Brennan TA, Hebert LE, Laird NM, et al. Hospital characteristics associated with adverse events and substandard care. JAMA 1991; 265(24): 3265–9PubMedCrossRef
33.
go back to reference Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984; 2(8402): 564–7PubMedCrossRef Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984; 2(8402): 564–7PubMedCrossRef
34.
go back to reference Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49(9): 2229–32PubMed Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49(9): 2229–32PubMed
35.
go back to reference Kelly WN. Potential risks and prevention: part 1. Fatal adverse drug events. Am J Health SystPharm 2001; 58(14): 1317–24 Kelly WN. Potential risks and prevention: part 1. Fatal adverse drug events. Am J Health SystPharm 2001; 58(14): 1317–24
36.
go back to reference Kelly WN. Potential risks and prevention: part 2. Drug-induced permanent disabilities. Am J Health Syst Pharm 2001; 58(14): 1325–9PubMed Kelly WN. Potential risks and prevention: part 2. Drug-induced permanent disabilities. Am J Health Syst Pharm 2001; 58(14): 1325–9PubMed
37.
go back to reference Marcellino K, Kelly WN. Potential risks and prevention: part 3. Drug-induced threats to life. Am J Health Syst Pharm 2001; 58(15): 1399–405PubMed Marcellino K, Kelly WN. Potential risks and prevention: part 3. Drug-induced threats to life. Am J Health Syst Pharm 2001; 58(15): 1399–405PubMed
38.
go back to reference Kelly WN. Potential risks and prevention: part 4. Reports of significant adverse drug events. Am J Health Syst Pharm 2001; 58(15): 1406–12PubMed Kelly WN. Potential risks and prevention: part 4. Reports of significant adverse drug events. Am J Health Syst Pharm 2001; 58(15): 1406–12PubMed
39.
go back to reference Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538PubMed Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538PubMed
40.
go back to reference Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33(2): 236–40PubMedCrossRef Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33(2): 236–40PubMedCrossRef
41.
go back to reference Ruiz B, García M, Aguirre U, et al. Factors predicting hospital readmissions related to adverse drug reactions. Eur J Clin Pharmacol 2008; 64(7): 715–22PubMedCrossRef Ruiz B, García M, Aguirre U, et al. Factors predicting hospital readmissions related to adverse drug reactions. Eur J Clin Pharmacol 2008; 64(7): 715–22PubMedCrossRef
42.
go back to reference Leendertse AJ, Egberts ACG, Stoker LJ, et al., the HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168(17): 1890–6PubMedCrossRef Leendertse AJ, Egberts ACG, Stoker LJ, et al., the HARM Study Group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168(17): 1890–6PubMedCrossRef
43.
go back to reference Kunac DL, Reith DM. Preventable medication-related events in hospitalised children in New Zealand. N Z Med J 2008; 121: 17–32PubMed Kunac DL, Reith DM. Preventable medication-related events in hospitalised children in New Zealand. N Z Med J 2008; 121: 17–32PubMed
44.
go back to reference Ducharme MM, Boothby LA. Analysis of adverse drug reactions for preventability. Int J Clin Pract 2007; 61(1): 157–61PubMedCrossRef Ducharme MM, Boothby LA. Analysis of adverse drug reactions for preventability. Int J Clin Pract 2007; 61(1): 157–61PubMedCrossRef
45.
go back to reference Dormann H, Neubert A, Criegee-Rieck M, et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med 2004; 255: 653–63PubMedCrossRef Dormann H, Neubert A, Criegee-Rieck M, et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med 2004; 255: 653–63PubMedCrossRef
46.
go back to reference Snyder RA, Abarca J, Meza JL, et al. Reliability evaluation of the adapted national coordinating council medication error reporting and prevention (NCC MERP) index. Pharmacoepidemiol Drug Saf 2007; 16: 1006–13PubMedCrossRef Snyder RA, Abarca J, Meza JL, et al. Reliability evaluation of the adapted national coordinating council medication error reporting and prevention (NCC MERP) index. Pharmacoepidemiol Drug Saf 2007; 16: 1006–13PubMedCrossRef
47.
go back to reference Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ (Clin Res Ed) 1981; 282: 974–6CrossRef Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ (Clin Res Ed) 1981; 282: 974–6CrossRef
48.
go back to reference Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851–70PubMedCrossRef Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28(10): 851–70PubMedCrossRef
49.
go back to reference Jonville-Béra AP, Saissi H, Bensouda-Grimaldi L, et al. Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre. Drug Saf 2009; 32(5): 429–40PubMedCrossRef Jonville-Béra AP, Saissi H, Bensouda-Grimaldi L, et al. Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre. Drug Saf 2009; 32(5): 429–40PubMedCrossRef
50.
go back to reference Anonymous. Failings in treatment advice, SPCs and black triangles. Drug Ther Bull 2001; 39(4): 25–7CrossRef Anonymous. Failings in treatment advice, SPCs and black triangles. Drug Ther Bull 2001; 39(4): 25–7CrossRef
51.
go back to reference Bates DW, O’Neil AC, Boyle D, et al. Potential identifiability and preventability of adverse events using information systems. J Am Med Inform Assoc 1994; 1(5): 404–11PubMedCrossRef Bates DW, O’Neil AC, Boyle D, et al. Potential identifiability and preventability of adverse events using information systems. J Am Med Inform Assoc 1994; 1(5): 404–11PubMedCrossRef
52.
go back to reference Bobb A, Gleason K, Husch M, et al. The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med 2004; 164(7): 785–92PubMedCrossRef Bobb A, Gleason K, Husch M, et al. The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med 2004; 164(7): 785–92PubMedCrossRef
53.
go back to reference Kuo GM, Phillips RL, Graham D, et al. Medication errors reported by US family physicians and their office staff. Qual Saf Health Care 2008; 17: 286–90PubMedCrossRef Kuo GM, Phillips RL, Graham D, et al. Medication errors reported by US family physicians and their office staff. Qual Saf Health Care 2008; 17: 286–90PubMedCrossRef
54.
go back to reference van der Sijs H, Vulto A, Berg M. Overriding of drug safety alerts in Computerized Physician Order Entry. J Am Med Inform Assoc 2006; 13: 138–47PubMedCrossRef van der Sijs H, Vulto A, Berg M. Overriding of drug safety alerts in Computerized Physician Order Entry. J Am Med Inform Assoc 2006; 13: 138–47PubMedCrossRef
55.
go back to reference Silverman JB, Stapinski CD, Churchill WW, et al. Multi-faceted approach to reducing preventable adverse drug events. Am J Health Syst Pharm 2003; 60(6): 582–6PubMed Silverman JB, Stapinski CD, Churchill WW, et al. Multi-faceted approach to reducing preventable adverse drug events. Am J Health Syst Pharm 2003; 60(6): 582–6PubMed
56.
go back to reference Aronson JK. Medication errors: definitions and classification. Br J Clin Pharmacol 2009; 67(6): 599–604PubMedCrossRef Aronson JK. Medication errors: definitions and classification. Br J Clin Pharmacol 2009; 67(6): 599–604PubMedCrossRef
57.
go back to reference Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151(9): 1825–32PubMedCrossRef Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151(9): 1825–32PubMedCrossRef
58.
go back to reference Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14): 1531–6PubMedCrossRef Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14): 1531–6PubMedCrossRef
59.
go back to reference Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163(22): 2716–24PubMedCrossRef Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163(22): 2716–24PubMedCrossRef
60.
go back to reference Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147(11): 755–65PubMedCrossRef Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147(11): 755–65PubMedCrossRef
61.
go back to reference Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults. Clin Ther 2002; 24(10): 1595–613PubMedCrossRef Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults. Clin Ther 2002; 24(10): 1595–613PubMedCrossRef
62.
go back to reference Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Health Syst Pharm 1990; 47: 533–43 Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Health Syst Pharm 1990; 47: 533–43
63.
go back to reference MacKinnon NJ, Hepler CD. Indicators of preventable drug-related morbidity in older adults: 2. Use within a managed care organization. J Manag Care Pharm 2003; 9(2): 134–41PubMed MacKinnon NJ, Hepler CD. Indicators of preventable drug-related morbidity in older adults: 2. Use within a managed care organization. J Manag Care Pharm 2003; 9(2): 134–41PubMed
64.
go back to reference Howard RL, Avery AJ, Howard PD, et al. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003; 12(4): 280–5PubMedCrossRef Howard RL, Avery AJ, Howard PD, et al. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003; 12(4): 280–5PubMedCrossRef
65.
go back to reference Baena MI, Marin R, Martinez Olmos J, et al. Nuevos criterios para determiner la evidabilidad de los problemas relacionados con los medicamentos. Una revisión actualizada a partir de la experiencia con 2558 personas. Pharm Care Esp 2002; 4: 393–6 Baena MI, Marin R, Martinez Olmos J, et al. Nuevos criterios para determiner la evidabilidad de los problemas relacionados con los medicamentos. Una revisión actualizada a partir de la experiencia con 2558 personas. Pharm Care Esp 2002; 4: 393–6
66.
go back to reference Olivier P, Caron J, Haramburu F, et al. Validation d’une éhelle de mesure: exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Thérapie 2005; 60(1): 39–45PubMedCrossRef Olivier P, Caron J, Haramburu F, et al. Validation d’une éhelle de mesure: exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Thérapie 2005; 60(1): 39–45PubMedCrossRef
67.
go back to reference Winterstein AG, Sauer BC, Hepler CD, et al. Preventable drug-related hospital admissions. Ann Pharmacother 2002; 36(7–8): 1238–48PubMedCrossRef Winterstein AG, Sauer BC, Hepler CD, et al. Preventable drug-related hospital admissions. Ann Pharmacother 2002; 36(7–8): 1238–48PubMedCrossRef
Metadata
Title
Preventability of Drug-Related Harms — Part I
A Systematic Review
Authors
Professor Robin E. Ferner
Jeffrey K. Aronson
Publication date
01-11-2010
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 11/2010
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11538270-000000000-00000

Other articles of this Issue 11/2010

Drug Safety 11/2010 Go to the issue